



J. K. JAIN & ASSOCIATES

CHARTERED ACCOUNTANTS

S.C.O. 1132-33, Sector 22-B, CHANDIGARH - 160 022

0172-270 4536-37 Fax : 0172-270 4537

E-mail : jkjcaps@rediffmail.com

REVIEW REPORT

The Board of Directors,
Brooks Laboratories Limited
G-101, Ivory Tower
Sector 70
Mohali

We have reviewed the accompanying statement of un-audited Financial Results of **Brooks Laboratories Limited** for the Quarter/Nine months ended. 31.12.2011. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, 'Engagements to Review financial statements' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of un-audited Quarterly financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 41 of the listing agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for J. K. Jain & Associates,
(Chartered Accountants)

-Sd-

(J.K.Jain)

Partner

M.No. 083140

Firm No. 004025N

Date : 15.02.2012
Place : Chandigarh

BROOKS LABORATORIES LIMITED
Regd office: G 101, Ivory Tower, Sector 70, Mohali, Punjab

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 31st DECEMBER, 2011

Particulars		(₹ In Lakhs) STANDALONE			
		Quarter ended	Quarter ended	Nine months ended	Year Ended
		31.12.2011	30.9.2011	31.12.2011	31.03.2011
		Unaudited	Unaudited	Unaudited	Audited
1	(a) Net Sales/Income from Operations	1554.05	1435.45	4160.05	5253.92
	(b) Other Operating Income	-	-	-	-
	Total Income	1554.05	1435.45	4160.05	5253.92
2	Expenditure				
	a. (Increase)/decrease in stock in trade and work in progress	58.19	56.13	139.09	-42.01
	b. Consumption of raw materials	959.66	890.16	2647.11	3746.50
	c. Employees cost	76.10	50.32	180.34	235.53
	d. Depreciation	16.26	16.18	48.17	60.30
	e. Other expenditure				
	-Manufacturing Expenses	95.45	68.74	201.03	221.98
	-Other Expenses	79.84	77.46	229.01	165.22
	g. Total	1285.50	1158.99	3444.74	4387.52
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	268.55	276.46	715.31	866.39
4	Other Income	37.30	13.22	51.26	24.01
5	Profit before Interest and Exceptional Items (3+4)	305.85	289.68	766.57	890.41
6	Finance Charges	2.27	27.60	56.60	160.76
7	Profit after Interest but before Exceptional Items (5-6)	303.58	262.08	709.97	729.64
8	Exceptional items	-	-	-	-

9	Profit from Ordinary Activities before tax (7-8)	303.58	262.08	709.97	729.64
10	Tax expense				
	-Current Tax	60.74	52.44	142.05	145.42
	-MAT Credit Unutilized	56.17	48.48	131.35	131.34
	-Deferred Tax	3.31	3.12	9.62	16.07
11	Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	295.70	255.00	689.65	699.49
12	Extraordinary Items	-	-	-	10.67
13	Net Profit(+)/ Loss(-) for the period (11-12)	295.70	255.00	689.65	688.82
14	Paid-up equity share capital (Face Value : Rs 10 each)	1618.64	1618.64	1618.64	988.64
15	Reserve excluding Revaluation Reserves	-	-	-	954.09
16	Earnings Per Share				
a)	Basic earning per share before extra - ordinary items Rs.	3.12	4.72	7.27	7.08
	Diluted earnings per share before extra ordinary items Rs.	3.12	4.72	7.27	7.12
b)	Basic earning per share after extra - ordinary items Rs.	3.12	4.72	7.27	6.97
	Diluted earnings per share after extra ordinary items Rs.	3.12	4.72	7.27	7.00
17	Public Shareholding				
	- No. of shares	6300000	6300000	6300000	-
	- Percentage of shareholding	38.92	38.92	38.92	-
	Others (Office Bearers)	50000	50000	50000	50000
18	Promoters and promoter group Shareholding **				
a)	Pledged/Encumbered				
	- Number of Shares				
	- Percentage of shares (as a% of the total shareholding of promoter and promoter group)				
	- Percentage of shares (as a % of the total share capital of the company)				
b)	Non-encumbered				
	- Number of Shares	9836422	9836422	9836422	9836422
	- Percentage of shares (as a% of the total shareholding of promoter and promoter group)	100	100	100	100
	- Percentage of shares (as a % of the total share capital of the company)	60.77	60.77	60.77	100

Detail of cost of Project status as on 31th December 2011.

(₹ in Lakhs)

Sr.No.	Object	Total Estimated Cost	Actual Utilizations
1	Land	635.00	63.30
2	Advance given for Building Construction	1220.00	1200.00
3	Advance given for Purchase of Plant & Machinery	1994.00	547.49
4	Advance given for Utilities	1100.00	850.00
5	Advance given for Purchase of Misc. Fixed Assets	230.00	200.00
6	Long term working capital	500.00	NIL
7	General corporate purposes	328.29	33.87
8	Listing Fees to Stock Exchanges	0.96	0.96
9	Issue Expenses	291.75	291.75
	Total Cost of the Project	6300.00	3187.37

Notes:

- 1) The above result for the period ended 31st December 2011, as reviewed by the Audit Committee, were considered and approved by the Board of Directors at its meeting held on 15th February 2012, and were subjected to "Limited Review" by the Statutory auditors.
- 2) As the company's business activity falls within a single primary business segment "Pharmaceutical Formulations" the Disclosure Requirement of Accounting Standard (AS-17) "Segment Reporting" is not applicable.
- 3) The Statutory Auditors have carried out Limited Review of the above Un- Audited Financial result in terms of the clause 41 of the Listing Agreement.
- 4) Figures for the previous year/period have been regrouped, wherever necessary.
- 5) The company did not have any investor complaints pending as on 31st December 2011, there were no investor's complaints received during the quarter ended 31st December 2011.
- 6) The Equity Shares of the company got listed on BSE and NSE as on 5th September 2011 hence figure for the corresponding quarter/nine months ended 31st December 2010 are not given.

Place: **PUNJAB**

Date: **15th FEBRUARY 2012**

FOR BROOKS LABORATORIES LIMITED



MANAGING DIRECTOR

MR. RAJESH MAHAJAN